Foto del docente

Francesca Fornari

Professoressa associata

Dipartimento di Scienze per la Qualità della Vita

Settore scientifico disciplinare: BIOS-09/A Biochimica clinica e biologia molecolare clinica

Pubblicazioni

vai alle Pubblicazioni

Pubblicazioni antecedenti il 2004

  1. Non-coding RNAs in hepatocellular carcinoma: potential applications in combined therapeutic strategies and promising candidates of treatment response. Vianello C, Monti E, Leoni I, Galvani G, Giovannini C, Piscaglia F, Stefanelli C, Gramantieri L, Fornari F. Cancers 2024. 16(4):766. (Review). IF 5.2
  2. Circulating CD8 lymphocytes predict response to atezolizumab-bevacizumab in hepatocellular carcinoma. [https://pubmed.ncbi.nlm.nih.gov/37990855/] Gramantieri L, Suzzi F, Bassi C, D'Abundo L, Tovoli F, Bruccoleri M, Marseglia M, Alimenti E, Fornari F, Negrini M, Iavarone M, Piscaglia F, Giovannini C. Eur J Immunol 2024. 54(2):e2350637. IF 6.688
  3. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma. Bergamini C, Leoni I, Rizzardi N, Melli M, Galvani G, Coada CA, Giovannini C, Monti E, Liparulo I, Valenti F, Ferracin M, Ravaioli M, Cescon M, Vasuri F, Piscaglia F, Negrini M, Stefanelli C, Fato R, Gramantieri L, Fornari F.
    J Exp Clin Cancer Res 2023. 42(1):145. IF 12.568
  4. Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab-Bevacizumab in Hepatocellular Carcinoma. [https://pubmed.ncbi.nlm.nih.gov/36980547/] Giovannini C, Suzzi F, Tovoli F, Bruccoleri M, Marseglia M, Alimenti E, Fornari F, Iavarone M, Piscaglia F, Gramantieri L. Cancers 2023. 15(6):1661. IF 6.126
  5. Animal models of hepatocellular carcinoma: current applications in clinical research. Fornari F, Giovannini C, Piscaglia F, Gramantieri L. J Hepatocell Carcinoma 2022. (Review). IF 4.962
  6. MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much s missing? Gramantieri L, Fornari F. Oncoscience 2022. 9:52-54 (Editorial)
  7. MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. Gramantieri L, Fornari F, Giovannini C, Trerè D. Biomolecules 2022. (Review). IF 5.88
  8. Aflatoxin B1 DNA-adducts in hepatocellular carcinoma from a low-exposure area. Gramantieri L, Gnudi F, Vasuri F, Mandrioli M, Fornari F, Tovoli F, Suzzi F, Vornoli A, D’Errico A, Piscaglia F, Giovannini C. Nutrients 2022. 14(8)-1652. IF 5.719
  9. Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma. Fornari F, Gramantieri L. MicroRNA in Human Malignancy 2022. pp. 301-315. (Book chapter)
  10. Hepatic cancer stem cells: molecular mechanisms, therapeutic implications, and circulating biomarkers. Gramantieri L, Giovannini C, Suzzi F, Leoni I, Fornari F. Cancers 2021. 13(18):4550. (Review). IF 6.126
  11. Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions. Fornari F, Giovannini C, Piscaglia F, Gramantieri L. J Hepatocell Carcinoma 2021. 8:741-757. (Review). IF 4.655
  12. MicroRNA as modulators of tumor metabolism, microenvironment and immune response in hepatocellular carcinoma. Gramantieri L, Giovannini C, Piscaglia F, Fornari F. J Hepatocell Carcinoma 2021. 8:369-385. (Review). IF 4.655
  13. Notch signaling regulation in HCC: from hepatitis virus to non-coding RNAs. Giovannini C, Fornari F, Piscaglia F, Gramantieri L. Cells 2021. 10:521. (Review). IF 4.366
  14. Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma. Giovannini C, Fornari F, Indio V, Trerè D, Renzulli M, Vasuri F, Cescon M, Ravaioli M, Perrucci A, Astolfi A, Piscaglia F, Gramantieri L. Cancers 2020. 12(9):2674. IF 6.162
  15. Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE study. Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, Giuseppe Foschi F, Tamburini E, Vivaldi C, Domenico Rizzato M, Ielasi L, Canale M, Conti F, Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino G, Lonardi S, Fornari F, Orsi G, Rovesti G, Zagonel V, Cascinu C, Scartozzi M. Clin Cancer Res 2020. 26(17):4485-93. IF 8.911
  16. MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma. Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M, Casadei-Gardini M, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F. Cancer Res 2020. 80:1720-34. IF 8.378
  17. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. Kowalik MA, Puliga E, Cabras L, Sulas P, Petrelli A, Perra A, Ledda-Columbano GM, Morandi A, Merlin S, Orrù C, Sanchez-Martin C, Fornari F, Gramantieri L, Parri M, Rasola A, Bellomo SE, Sebastian C, Follenzi A, Giordano S, Columbano A. J Hepatol 2020. 72(6):1159-1169. IF 18.946
  18. MicroRNA in animal models of HCC. Fornari F, Gramantieri L, Piscaglia F, Giovannini C. Cancers 2019. 11(12). pii: E1906. (Review). IF 6.162
  19. Animal models of hepatocellular carcinoma prevention. Shankaraiah R, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Cancers 2019. 1(11). pii: E1792. (Review). IF 6.162
  20. MiR-122 targets SerpinB3 and is involved in Sorafenib resistance in hepatocellular carcinoma. Turato C*, Fornari F*, Pollutri D, Fassan M, Quarta S, Villano G, Ruvoletto M, Bolondi L, Gramantieri L, Pontisso P. J Clin Med2019. 1:8(2). IF 5.583
  21. MicroRNA-based prophylaxis in a mouse model of cirrhosis and liver cancer. Callegari E. Domenicali M, Shankaraiah R, D’Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin B, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini E, Gramantieri L, Sabbioni S, Negrini M. Mol Ther Nucleic Acids 2019. 14:239-50. IF 5.660
  22. LncRNAs as novel players in hepatocellular carcinoma recurrence. Gramantieri L, Baglioni M, Fornari F, Laginestra MA, Ferracin M, Indio V, Ravaioli M, Cescon M, De Pace V, Leoni S, Coadă CA, Negrini M, Bolondi L, Giovannini C. Oncotarget 2018.9:35085-99. IF 5.168
  23. MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. Giovannini C*, Fornari F*, Dallo R, Gagliardi M, Nipoti E, Vasuri F, Coada C, Ravaioli M, Bolondi L, Gramantieri L. Acta Histochem 2018. 120:95-102. IF 1.652
  24. Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Moshiri F, Salvi A, Gramantieri L, Sangiovanni A, Guerriero P, De Petro G, Bassi C, Lupini L, Sattari A, Cheung D, Veneziano D, Nigita G, Shankaraiah RC, Portolani N, Carcoforo P, Fornari F, Bolondi L, Frassoldati A, Sabbioni S, Colombo M, Croce CM, Negrini M. Oncotarget 2018. 9:15350-64. IF 5.168
  25. The epigenetically regulated miR-494 associates with stem cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Pollutri D, Patrizi C, Marinelli S, Giovannini C, Trombetta E, Giannone AF, Baldassarre M, Quarta S, Vandewynckel YP, Vandierendonck A, Van Vlierberghe A, Porretti L, Negrini M, Bolondi L, Gramantieri L, Fornari F. Cell Death Dis 2018. 9(1):4. IF 5.638
  26. In hepatocellular carcinoma miR-221 modulates Sorafenib resistance through inhibition of caspase-3 mediated apoptosis. Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, Casadei Gardini A, Marisi G, Baron Toaldo M, Baglioni M, Salvatore V, Callegari E, Baldassarre M, Galassi M, Giovannini C, Cescon M, Ravaioli M, Negrini M, Bolondi L, Gramantieri L. Clin Cancer Res 2017. 23:3953-65. IF 10.199.
  27. TP53/microRNA interplay in hepatocellular carcinoma. Pollutri P, Gramantieri L, Bolondi L, Fornari F. Int J Mol Sci 2016. 17 (12). (Review). IF 3.226
  28. Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate. Brighenti E, Giannone FA, Fornari F, Onofrillo C, Govoni M, Montanaro L, Trerè D, Derenzini D. Oncotarget 2016. 7:63226-41. IF 5.168
  29. Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic cencerogenesis. Kowalik MA, Guzzo G, Morandi A, Perra A, Menegon S, Magras I, Trevisan E, Angioni MM, Fornari F, Quagliata L, Ledda-Columbano GM, Gramantieri L, Terracciano L, Giordano S, Chiarugi P, Rasola A, Columbano A. Oncotarget 2016. 7:32375-93. IF 5.168
  30. The metabolic gene HAO2 is down regulated in mouse, rat and human hepatocellular carcinoma and correlates with metastasis and poor survival. Mattu S*, Fornari F*, Quagliata L*, Perra A, Angioni MM, Petrelli A, Menegon S, Ledda-Columbano GM, Gramantieri L, Terracciano L, Giordano S, Columbano A. J Hepatol 2016. 64:891-898. IF 12.486
  31. Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Lupini L, Pepe F, Ferracin M, Braconi C, Callegari E, Pagotto S, Spizzo R, Zagatti B, Lanuti P, Fornari F, Ghasemi R, Mariani-Costantini R, Bolondi L, Gramantieri L, Calin GA, Sabbioni S, Visone R, Veronese A, Negrini M. Oncotarget 2016. 7:31361-71. IF 5.168
  32. Direct relationship between the level of p53 stabilization induced by rRNA synthesis- inhibiting drugs and the cell ribosome biogenesis rate. Scala F, Brighenti E, Govoni M, Imbrogno E, Fornari F, Trerè D, Montanaro L, Derenzini M. Oncogene 2016. 35:977-89. IF 7.519
  33. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC. Fornari F, Ferracin M, Trerè D, Milazzo M, Marinelli S, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borghi A, Foschi FG, Stefanini GF, Negrini M, Bolondi L, Gramantieri L. PLoS ONE 2015. 10:e0141448. IF 4.411
  34. Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC. Frau C, Loi R, Petrelli A, Perra A, Menegon S, Kowalik MA, Pinna S, Leoni VP, Fornari F, Gramantieri L, Ledda-Columbano GM, Giordano S, Columbano A. Hepatology 2015. 61:249-59. IF 10.59
  35. Suppression of p53 by Notch3 is mediated by cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Giovannini C, Minguzzi M, Baglioni M, Fornari F, Giannone F, Ravaioli M, Cescon M, Chieco P, Bolondi L, Gramantieri L. Oncotarget 2014. 15:10607-20. IF 6.359
  36. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. Fornari F, Milazzo M, Galassi M, Callegari E, Veronese A, Miyaaki H, Sabbioni S, Mantovani V, Marasco E, Chieco P, Negrini M, Bolondi L, Gramantieri L. Mol Cancer Res 2014. 12:203-16. IF 4.38
  37. The natural inhibitor of DNA Topoisomerase I, Camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. Bertozzi D, Marinello J, Manzo SG, Fornari F, Gramantieri L, Capranico G. Mol Cancer Ther 2014. 13:239-48. IF 5.683
  38. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L, Nakao K. Liver Int 2014. 34:e302-7. IF 4.85
  39. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. Callegari E, Elamin BK, D’Abundo L, Falzoni S, Donvito G, Moshiri F, Milazzo M, Altavilla G, Giacomelli L, Fornari F, Hemminki A, Di Virgilio F, Gramantieri L, Negrini M, Sabbioni S. Plos ONE 2013. 8:e73964. IF 3.534
  40. CDKN1C/p57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma. Giovannini C, Gramantieri L, Minguzzi M, Fornari F, Chieco P, Grazi GL, Bolondi L. Am J Pathol 2012. 181:413-22. IF 4.522
  41. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. [http://www.ncbi.nlm.nih.gov/pubmed/22473819] Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D'Abundo L, Ferracin M, Bassi C, Zagatti B, Corrà F, Miotto E, Lupini L, Bolondi L, Gramantieri L, Croce CM, Sabbioni S, Negrini M. Hepatology 2012. 56:1025-33. IF 9.858
  42. In hepatocellular carcinoma miR-519d is upregulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, Capranico G, Mantovani V, Marinello J, Sabbioni S, Callegari E, Cescon M, Ravaioli M, Croce CM, Bolondi L, Gramantieri L. J Pathol 2012. 227:275-85. IF 7.585
  43. Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. Strocchi E, Fornari F, Minguzzi M, Gramantieri L, Milazzo M, Rebuttini V, Breviglieri S, Camaggi CM, Locatelli E, Bolondi L, Comes-Franchini M. Eur J Med Chem 2012. 48:391-401. IF 3.48
  44. MicroRNA and hepatocellular carcinoma: biology and prognostic significance. Milazzo M, Fornari F, Gramantieri L. Minerva Gastroenterol e Dietol 2011. 57:257-71. (Review).
  45. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L. Cancer Res 2010. 70: 5184-93. IF 8.234
  46. Oncogenic role of miR-483-3p at the IGF2/483 locus. Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, Zanesi N, Alder H, D'Elia G, Gramantieri L, Bolondi L, Lanza G, Querzoli P, Angioni A, Croce CM, Negrini M. Cancer Res 2010. 70:3140-49. IF 8.234
  47. In hepatocellular carcinoma microRNA-221 targets Bmf and correlates with tumor multifocality. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M. Clin Cancer Res 2009. 15:5073-81. IF 6.747
  48. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L. Cancer Res 2009. 69:5761-67. IF 7.543
  49. MicroRNA involvement in hepatocellular carcinoma. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M. J Cell Mol Med 2008. 12: 2189-204. (Review). IF 5.114
  50. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M. Oncogene 2008. 27:5651-61. IF 7.216
  51. Cyclin G1 is target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. Cancer Res 2007. 67:6092-99. IF 7.67